
Sanofi has scrapped its regulatory filing plans and late-stage trials for rare bone marrow cancer treatment fedratinib. The reason given …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

